Evaluation of Thyroid Abnormity Incidence and Thyroid Toxicity During Chemotherapy Among Newly Diagnosed Breast Cancer

Inclusion criteria

• Female patients with histologically or cytologically proven primary breast cancer;
• Age >18 years;
• ECOG Performance Status: 0-2;
• Life Expectancy: 3 months or more;
• No previous anti-cancer therapy;
• Be willing to undergo at least four cycles of anthracycline or taxane-based chemotherapy;
• Adequate hematological, liver, and kidney functions.

Exclusion criteria

• Pregnancy or lactation;
• History of other malignancy or secondary breast cancer;
• History of thyroid disease;
• History of drug addiction or abuse;
• History of immunodeficiency disease;
• Treatment with drugs capable of influencing thyroid gland functions within 3 months prior to study entry;
• Nonmeasurable disease such as un-controlled diabetes, severe cardiovascular and cerebrovascular diseases;
• Current, recent (within 4 weeks prior to study entry), or planned participation in any other clinical trials;
• Inability to understand and agree to informed consent.